Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de escalonamento de dose de fase 1 de SLV 154 em indivíduos com tumores sólidos metastáticos

18 de setembro de 2026 atualizado por: Solve Therapeutics

This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

Visão geral do estudo

Status

Recrutamento

Intervenção / Tratamento

Descrição detalhada

A Bayesian optimal interval (BOIN) design with a target dose-limiting toxicity (DLT) rate for the maximum tolerated dose (MTD) of 27% and an estimated maximum sample size of ~70 subjects will be used to guide the dose escalation and determine the recommended dosing regimen (RDR) of SLV-154. Once the initial RDR is established in the Phase 1a portion of this study, further development in the Phase 1b expansion portion of this study will be considered in patients with specific cancers. In the Phase 1b part of this study, enrollment of each tumor-specific cohort will be performed using a Simon 2-stage optimal design.

SLV-154 will be administered intravenously (IV) in repeated 3-week cycles. Treatment will continue until progressive disease or discontinuation.

Tipo de estudo

Intervencional

Inscrição (Estimado)

250

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • California
      • Newport Beach, California, Estados Unidos, 92663
        • Recrutamento
        • Hoag Memorial Hospital Presbyterian
        • Contato:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Recrutamento
        • Washington University
        • Contato:
    • New Jersey
      • East Brunswick, New Jersey, Estados Unidos, 08816
    • New York
      • New York, New York, Estados Unidos, 10065
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center
        • Contato:
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • Recrutamento
        • University Hospitals Cleveland Medical Center
        • Contato:
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • The James Outpatient Care West Center
        • Contato:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19111
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • MD Anderson Cancer Center
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
      • San Antonio, Texas, Estados Unidos, 78229
        • Recrutamento
        • Mays Cancer Center; University of Texas Health San Antonio
        • Investigador principal:
          • Daruka Mahadevan
        • Contato:
    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • Recrutamento
        • University of Washington / Fred Hutchinson Cancer Center
        • Contato:
      • Tacoma, Washington, Estados Unidos, 98405
        • Recrutamento
        • Northwest Medical Specialties, PLLC
        • Contato:
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Men or women (as appropriate for cancer type) of age ≥12 years.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  3. Histologically or cytologically confirmed diagnosis of advanced cancer as documented in medical records.
  4. Presence of metastatic or recurrent locally advanced cancer.
  5. Presence of radiographically measurable disease.
  6. Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options).
  7. Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
  8. Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
  9. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
  10. Adequate hematological profile.
  11. Adequate coagulation profile.
  12. Adequate hepatic profile.
  13. Adequate renal function.
  14. Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
  15. For female subjects of childbearing potential, a negative serum pregnancy test.
  16. For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
  17. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
  18. Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
  19. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

Exclusion Criteria:

  1. Unstable malignancy involving the central nervous system.
  2. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
  3. Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
  4. Significant cardiovascular event or comorbidity.
  5. Significant screening ECG abnormalities.
  6. Pregnancy or breastfeeding.
  7. Major surgery within 3 weeks before the start of study therapy.
  8. Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.
  9. Concurrent participation in another therapeutic or imaging clinical trial.
  10. Other conditions likely to interfere with a subject's ability to participate in the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dose Level 1

0.75 mg/kg

SLV-154

Experimental: Dose Level 2

1.5 mg/kg

SLV-154

Experimental: Dose Level 3

3.0 mg/kg

SLV-154

Experimental: Dose Level 4

4.0 mg/kg

SLV-154

Experimental: Dose Level 5

5.0 mg/kg

SLV-154

Experimental: Dose Level 6

6.5 mg/kg

SLV-154

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Phase 1a: MTD and/or RDR
Prazo: Through the duration of treatment, up to approximately 18 months

Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-154.

Through the duration of treatment, up to approximately 18 months
Phase 1b: Objective response rate (ORR)
Prazo: Through the duration of treatment, up to approximately 18 months

ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR).

Through the duration of treatment, up to approximately 18 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
SLV-154 administration
Prazo: Through the duration of treatment, up to approximately 18 months

SLV-154 drug administration as assessed by prescribing records

Through the duration of treatment, up to approximately 18 months
SLV-154 Safety
Prazo: Through the duration of treatment, up to approximately 18 months

Collection of type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign/oxygen saturation abnormalities; adverse electrocardiogram (ECG) findings; DLTs; serious adverse events (SAEs); adverse events of special interest (AESIs); or adverse events (AEs) leading to interruption, modification, or discontinuation of study drug administration.

Through the duration of treatment, up to approximately 18 months
Evaluation of use of concomitant medications
Prazo: Through the duration of treatment, up to approximately 18 months

Type, frequency, and timing of use of supportive care and other concomitant medications

Through the duration of treatment, up to approximately 18 months
SLV-154 Pharmacokinetics
Prazo: Varying timepoints through the duration of treatment, up to approximately 18 months

Evaluation of the pharmacokinetic profile of SLV-154

Varying timepoints through the duration of treatment, up to approximately 18 months
Immunogenicity
Prazo: Varying timepoints through the duration of treatment, up to approximately 18 months

Measurement of changes in titers of circulating SLV 154-reactive antibodies (as assessed using immunoassay methods)

Varying timepoints through the duration of treatment, up to approximately 18 months
Time to Response (TTR)
Prazo: Up to approximately 36 months

TTR: interval from the start of study drug administration to the first documentation of objective tumor regression

Up to approximately 36 months
Duration of Response (DOR)
Prazo: Up to approximately 36 months

DOR: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause

Up to approximately 36 months
4-month progression-free survival (PFS4)
Prazo: Up to approximately 36 months

PFS4: proportion of subjects who are alive and have not experienced disease progression at 4 months after the start of study drug administration

Up to approximately 36 months
6-month progression-free survival (PFS6)
Prazo: Up to approximately 36 months

PFS6: proportion of subjects who are alive and have not experienced disease progression at 6 months after the start of study drug administration

Up to approximately 36 months
Time to treatment failure (TTF)
Prazo: Up to approximately 36 months

TTF: interval from the start of study drug administration to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause

Up to approximately 36 months
Overall survival (OS)
Prazo: Up to approximately 36 months

OS: interval from the start of study drug administration to death from any cause

Up to approximately 36 months
Disease benefit ratio (DBR)
Prazo: Up to approximately 36 months

DBR: proportion of subjects who experience CR, PR, or stable disease with tumor reduction (SDTR)

Up to approximately 36 months
Progression free survival (PFS)
Prazo: Up to approximately 36 months

PFS: interval from the start of study drug administration to the earlier of the first documentation of disease progression or death from any cause

Up to approximately 36 months
Duration of disease benefit (DDB)
Prazo: Up to approximately 36 months

DDB: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause in subjects with disease benefit

Up to approximately 36 months
Percent change in tumor dimensions
Prazo: Up to approximately 36 months

percent change from baseline in the sum of the longest diameters of non-nodal target lesions and the shortest diameters of nodal target lesions

Up to approximately 36 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

14 de maio de 2025

Conclusão Primária (Estimado)

1 de agosto de 2027

Conclusão do estudo (Estimado)

1 de novembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

3 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de janeiro de 2025

Primeira postagem (Real)

13 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Results will be presented in clinical study reports and publications. Individual participant data will not be shared with other researchers.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever